• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与亮氨酸重复激酶2(LRRK2)相关的帕金森病的认知概况。

Cognitive profile of LRRK2-related Parkinson's disease.

作者信息

Srivatsal Sindhu, Cholerton Brenna, Leverenz James B, Wszolek Zbigniew K, Uitti Ryan J, Dickson Dennis W, Weintraub Daniel, Trojanowski John Q, Van Deerlin Vivianna M, Quinn Joseph F, Chung Kathryn A, Peterson Amie L, Factor Stewart A, Wood-Siverio Cathy, Goldman Jennifer G, Stebbins Glenn T, Bernard Bryan, Ritz Beate, Rausch Rebecca, Espay Alberto J, Revilla Fredy J, Devoto Johnna, Rosenthal Liana S, Dawson Ted M, Albert Marilyn S, Mata Ignacio F, Hu Shu-Ching, Montine Kathleen S, Johnson Catherine, Montine Thomas J, Edwards Karen L, Zhang Jing, Zabetian Cyrus P

机构信息

Virginia Mason Neuroscience Institute, Seattle, Washington, USA.

出版信息

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

DOI:10.1002/mds.26161
PMID:25650144
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4397146/
Abstract

BACKGROUND

Increasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2-related PD is not well-characterized.

METHODS

A cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.

RESULTS

LRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter-Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).

CONCLUSIONS

Our cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. © 2015 International Parkinson and Movement Disorder Society.

摘要

背景

越来越多的证据表明,遗传因素在帕金森病(PD)认知功能的变异性中发挥作用。LRRK2基因突变是单基因帕金森病最常见的病因;然而,LRRK2相关帕金森病的认知特征尚未得到充分描述。

方法

对帕金森病认知遗传学联盟招募的1447名帕金森病患者进行队列研究,筛查LRRK2基因突变,并完成详细的认知测试。使用线性回归模型评估突变携带者状态与认知测试分数之间的关联。

结果

LRRK2突变携带者(n = 29)在简易精神状态检查表(P = 0.03)和字母数字排序测试(P = 0.005)中表现更好。LRRK2携带者中痴呆的比例较小(P = 0.03)。

结论

我们的横断面研究表明,LRRK2相关帕金森病患者在某些认知测试中表现更好,痴呆发生率更低。未来需要进行纵向研究,以确定LRRK2突变携带者的认知衰退是否更慢。© 2015国际帕金森病和运动障碍协会。

相似文献

1
Cognitive profile of LRRK2-related Parkinson's disease.与亮氨酸重复激酶2(LRRK2)相关的帕金森病的认知概况。
Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.
2
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.帕金森病中与LRRK2基因R1441G突变相关的认知功能障碍。
Parkinsonism Relat Disord. 2014 Oct;20(10):1097-100. doi: 10.1016/j.parkreldis.2014.07.005. Epub 2014 Jul 30.
3
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.突尼斯 LRRK2 相关帕金森病患者的认知功能障碍。
Parkinsonism Relat Disord. 2012 Mar;18(3):243-6. doi: 10.1016/j.parkreldis.2011.10.009. Epub 2011 Nov 6.
4
Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.携带LRRK2基因G2019S和R1441G突变的帕金森病患者的认知和行为症状
Parkinsonism Relat Disord. 2015 May;21(5):494-9. doi: 10.1016/j.parkreldis.2015.02.019. Epub 2015 Mar 2.
5
Progression in the LRRK2-Asssociated Parkinson Disease Population.LRRK2 相关帕金森病人群的进展。
JAMA Neurol. 2018 Mar 1;75(3):312-319. doi: 10.1001/jamaneurol.2017.4019.
6
A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.一项针对未表现出症状的LRRK2和GBA基因携带者的认知功能磁共振成像研究。
Brain Struct Funct. 2017 Apr;222(3):1207-1218. doi: 10.1007/s00429-016-1271-4. Epub 2016 Jul 11.
7
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.早发性帕金森病 GBA 突变携带者的认知表现:CORE-PD 研究。
Neurology. 2012 May 1;78(18):1434-40. doi: 10.1212/WNL.0b013e318253d54b. Epub 2012 Mar 21.
8
Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.LRRK2 相关性帕金森病的运动表型:一项突尼斯纵向研究。
Mov Disord. 2015 Feb;30(2):253-8. doi: 10.1002/mds.26097. Epub 2014 Dec 9.
9
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.LRRK2相关帕金森病的表型、基因型及全球遗传外显率:一项病例对照研究。
Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6.
10
Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals.与LRRK2相关的帕金森病中的认知障碍:一项针对中国人群的研究。
Behav Neurol. 2015;2015:621873. doi: 10.1155/2015/621873. Epub 2015 Aug 6.

引用本文的文献

1
Cognitive Decline in Parkinsonism: From Clinical Phenotypes to the Genetic Background.帕金森病中的认知衰退:从临床表型到遗传背景
Biomedicines. 2025 Jul 2;13(7):1624. doi: 10.3390/biomedicines13071624.
2
Carriers of pathogenic variants show a milder, anatomically distinct brain signature of Parkinson's disease.携带致病变体的个体表现出一种较为轻微、在解剖学上有明显差异的帕金森病脑部特征。
medRxiv. 2025 Mar 10:2025.03.09.25323610. doi: 10.1101/2025.03.09.25323610.
3
LRRK2 mutation contributes to decreased free water in the nucleus basalis of Meynert in manifest and premanifest Parkinson's disease.LRRK2突变导致明显和前驱帕金森病患者中Meynert基底核的游离水减少。
J Neurol. 2024 Dec 12;272(1):33. doi: 10.1007/s00415-024-12811-5.
4
Bidirectional relationship between olfaction and Parkinson's disease.嗅觉与帕金森病之间的双向关系。
NPJ Parkinsons Dis. 2024 Dec 5;10(1):232. doi: 10.1038/s41531-024-00838-4.
5
Motor progression trajectories and risk of mild cognitive impairment in Parkinson's disease: A latent class trajectory model from PPMI cohort.帕金森病患者运动进展轨迹与轻度认知障碍风险:来自 PPMI 队列的潜在类别轨迹模型。
CNS Neurosci Ther. 2024 Aug;30(8):e14918. doi: 10.1111/cns.14918.
6
Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson's Disease.LRRK2蛋白相互作用组的转录组学和加权蛋白质网络分析揭示了散发性和LRRK2帕金森病的不同分子特征。
NPJ Parkinsons Dis. 2024 Aug 3;10(1):144. doi: 10.1038/s41531-024-00761-8.
7
Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.帕金森病精准治疗的新视角:通向个性化医疗新突破的多维度证据
Front Aging Neurosci. 2024 Jul 4;16:1417515. doi: 10.3389/fnagi.2024.1417515. eCollection 2024.
8
Investigation of the genetic aetiology of Lewy body diseases with and without dementia.伴有和不伴有痴呆的路易体病的遗传病因学研究。
Brain Commun. 2024 May 31;6(4):fcae190. doi: 10.1093/braincomms/fcae190. eCollection 2024.
9
Associations of cholinergic system integrity with cognitive decline in GBA1 and LRRK2 mutation carriers.GBA1和LRRK2突变携带者中胆碱能系统完整性与认知衰退的关联。
NPJ Parkinsons Dis. 2024 Jun 29;10(1):127. doi: 10.1038/s41531-024-00743-w.
10
The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.帕金森病执行功能综合量表:一种用于在临床试验中检测认知衰退的测量工具。
Neurology. 2024 Jul 23;103(2):e209609. doi: 10.1212/WNL.0000000000209609. Epub 2024 Jun 13.

本文引用的文献

1
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.LRRK2 相关性帕金森病路易体病理的临床相关性。
JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.
2
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.帕金森病中的APOE、MAPT和SNCA基因与认知表现
JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.
3
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.帕金森病中与LRRK2基因R1441G突变相关的认知功能障碍。
Parkinsonism Relat Disord. 2014 Oct;20(10):1097-100. doi: 10.1016/j.parkreldis.2014.07.005. Epub 2014 Jul 30.
4
Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.携带富含亮氨酸重复激酶2 G2019S突变的帕金森病的运动进展
Mov Disord. 2014 Jul;29(8):1057-60. doi: 10.1002/mds.25931. Epub 2014 Jun 5.
5
Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.帕金森病与富含亮氨酸重复激酶2 p.G2019S帕金森综合征的比较研究
Neurobiol Aging. 2014 May;35(5):1125-31. doi: 10.1016/j.neurobiolaging.2013.11.015. Epub 2013 Nov 22.
6
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.使用帕金森病轻度认知障碍运动障碍学会工作组标准定义认知障碍的最佳截断分数。
Mov Disord. 2013 Dec;28(14):1972-9. doi: 10.1002/mds.25655. Epub 2013 Oct 9.
7
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.太平洋西北奥德尔卓越临床联盟中心:研究设计和基线队列特征。
J Parkinsons Dis. 2013;3(2):205-14. doi: 10.3233/JPD-130189.
8
LRRK2: cause, risk, and mechanism.LRRK2:病因、风险因素和作用机制。
J Parkinsons Dis. 2013;3(2):85-103. doi: 10.3233/JPD-130192.
9
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.帕金森病伴与不伴 GBA 突变患者的临床和生化差异。
JAMA Neurol. 2013 Jul;70(7):852-8. doi: 10.1001/jamaneurol.2013.1274.
10
APOE ε4 increases risk for dementia in pure synucleinopathies.载脂蛋白 E ε4 增加纯突触核蛋白病患者发生痴呆的风险。
JAMA Neurol. 2013 Feb;70(2):223-8. doi: 10.1001/jamaneurol.2013.600.